01 4Avycaz
02 4Zavicefta
Main Therapeutic Indication : Gastrointestinal Disorders
Currency : USD
2017 Revenue in Millions : 61
2016 Revenue in Millions : 36
Growth (%) : 69
Main Therapeutic Indication : Gastrointestinal Disorders
Currency : USD
2018 Revenue in Millions : 95
2017 Revenue in Millions : 61
Growth (%) : 55%
Main Therapeutic Indication : Gastrointestinal Disorders
Currency : USD
2019 Revenue in Millions : 117
2018 Revenue in Millions : 95
Growth (%) : 23
Main Therapeutic Indication : Gastrointestinal Disorders
Currency : USD
2016 Revenue in Millions : 36
2015 Revenue in Millions : 23
Growth (%) : 57
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2020 Revenue in Millions : 212
2019 Revenue in Millions : 108
Growth (%) : 96
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2021 Revenue in Millions : 413
2020 Revenue in Millions : 212
Growth (%) : 95
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2022 Revenue in Millions : 412
2021 Revenue in Millions : 413
Growth (%) : 0
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2023 Revenue in Millions : 511
2022 Revenue in Millions : 412
Growth (%) : 24
LOOKING FOR A SUPPLIER?